DNER and hematopoietic and lymphoid cell neoplasm: The relevance of these proteins in the transcriptional control of malignant hematopoiesis makes pharmacological inhibition of BET protein activity particularly relevant to address the vulnerability of hematological cancers to BRD inhibitors [9].